These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 17138135)

  • 21. Breast metastasis from prostate cancer and interpretation of immunoreactivity to prostate-specific antigen.
    Cheng CW; Chan LW; Ng CF; Chan CK; Tse MK; Lai MM
    Int J Urol; 2006 Apr; 13(4):463-5. PubMed ID: 16734876
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer.
    Payne H; Cornford P
    Urol Oncol; 2011; 29(6):593-601. PubMed ID: 20060331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy.
    Fredolini C; Liotta LA; Petricoin EF
    Crit Rev Clin Lab Sci; 2010; 47(3):125-38. PubMed ID: 20858067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conference report and review: current status of biomarkers potentially associated with prostate cancer outcomes.
    Flaig TW; Nordeen SK; Lucia MS; Harrison GS; Glodé LM
    J Urol; 2007 Apr; 177(4):1229-37. PubMed ID: 17382696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA?
    Connolly D; Black A; Murray LJ; Nambirajan T; Keane PF; Gavin A
    Prostate Cancer Prostatic Dis; 2009; 12(1):47-51. PubMed ID: 18762815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Practical approaches to proteomic biomarkers within prostate cancer radiotherapy trials.
    Christensen E; Evans KR; Ménard C; Pintilie M; Bristow RG
    Cancer Metastasis Rev; 2008 Sep; 27(3):375-85. PubMed ID: 18427732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [New biomarkers for the prostate cancer].
    Ishii G; Kimura T; Kuruma H; Egawa S
    Nihon Rinsho; 2012 May; 70(5):828-32. PubMed ID: 22620008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
    Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
    Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simultaneous and exact interval estimates for the contrast of two groups based on an extremely high dimensional variable: application to mass spec data.
    Park Y; Downing SR; Kim D; Hahn WC; Li C; Kantoff PW; Wei LJ
    Bioinformatics; 2007 Jun; 23(12):1451-8. PubMed ID: 17459967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project.
    van Gils MP; Stenman UH; Schalken JA; Schröder FH; Luider TM; Lilja H; Bjartell A; Hamdy FC; Pettersson KS; Bischoff R; Takalo H; Nilsson O; Mulders PF; Bangma CH
    Eur Urol; 2005 Dec; 48(6):1031-41. PubMed ID: 16054748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prostate specific antigen (PSA) in the diagnosis and treatment of prostate carcinoma: advances and controversies].
    Popov I; Radosevic-Jelic Lj
    Srp Arh Celok Lek; 2001; 129(5-6):159-62. PubMed ID: 11797466
    [No Abstract]   [Full Text] [Related]  

  • 32. PSA and new biomarkers within multivariate models to improve early detection of prostate cancer.
    Stephan C; Cammann H; Meyer HA; Lein M; Jung K
    Cancer Lett; 2007 Apr; 249(1):18-29. PubMed ID: 17292541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Are multiple markers the future of prostate cancer diagnostics?
    Mikolajczyk SD; Song Y; Wong JR; Matson RS; Rittenhouse HG
    Clin Biochem; 2004 Jul; 37(7):519-28. PubMed ID: 15234233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Future directions in tumor marker technology for prostate cancer.
    Smith JA; Scaletsky R
    Urol Clin North Am; 1993 Nov; 20(4):771-7. PubMed ID: 7505985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Value of prostate specific antigen in early diagnosis of prostatic cancer].
    Xiao LP; Bi XJ; Li YN; Chen XQ; Zhang XF; Yu XP; Liu G; Yang MC; Song Z
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jan; 27(1):107-8, 112. PubMed ID: 17259162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
    Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH
    Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer.
    Schröder FH; Roobol MJ
    Curr Opin Urol; 2009 May; 19(3):227-31. PubMed ID: 19357513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psychological distress and prostate specific antigen levels in men with and without prostate cancer.
    Turner EL; Lane JA; Metcalfe C; Down L; Donovan JL; Hamdy F; Neal D; Vedhara K
    Brain Behav Immun; 2009 Nov; 23(8):1073-8. PubMed ID: 19486654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biomolecular and clinical characteristics of PSA and other candidate prostate tumor markers.
    Schellhammer PF; Wright GL
    Urol Clin North Am; 1993 Nov; 20(4):597-606. PubMed ID: 7505967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate-specific antigen kinetics in localized and advanced prostate cancer.
    Fitzpatrick JM; Banu E; Oudard S
    BJU Int; 2009 Mar; 103(5):578-87. PubMed ID: 19210674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.